OCIAD2

Across TCGA pan-cancer cohorts, OCIAD2 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of OCIAD2’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where OCIAD2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types OCIAD2 is over-expressed in tumor, although a few such as CCRCC show the opposite, repressed pattern.

PDAC, COAD, and HNSC are the cancer types where OCIAD2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in OCIAD2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Female	II,III,IV	+1.410	<.001	11	view →
COAD	Male	III,IV	+1.111	<.001	11	view →
HNSC	All	III,IV	+1.041	<.001	11	view →
CCRCC	Female	III,IV	−0.776	<.001	10	view →
LUAD	Female	II,III,IV	+1.976	<.001	9	view →
LSCC	Female	All	+1.451	<.001	9	view →
OV	All	All	+1.350	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

OCIAD2–PDAC

Open the PDAC breakdown →